In 2013, it was estimated that 95,688 people were living with multiple myeloma (MM) in the United States. This number is likely an underestimate, as many patients are not diagnosed or are not diagnosed early enough to make a meaningful contribution to the SEER database. Not surprisingly, many patients receive multiple lines of therapy, as relapse and resistance to previous treatments occur.

In 2013, it was estimated that 95,688 people were living with multiple myeloma (MM) in the United States.1

There is now availability of numerous chemotherapeutic options for MM treatment and these agents are often used as combination regimens.

In 2013, it was estimated that 95,688 people were living with multiple myeloma (MM) in the United States.1

There is now availability of numerous chemotherapeutic options for MM treatment and these agents are often used as combination regimens.

In 2013, it was estimated that 95,688 people were living with multiple myeloma (MM) in the United States.1

There is now availability of numerous chemotherapeutic options for MM treatment and these agents are often used as combination regimens.

In 2013, it was estimated that 95,688 people were living with multiple myeloma (MM) in the United States.1

There is now availability of numerous chemotherapeutic options for MM treatment and these agents are often used as combination regimens.

In 2013, it was estimated that 95,688 people were living with multiple myeloma (MM) in the United States.1

There is now availability of numerous chemotherapeutic options for MM treatment and these agents are often used as combination regimens.

In 2013, it was estimated that 95,688 people were living with multiple myeloma (MM) in the United States.1

There is now availability of numerous chemotherapeutic options for MM treatment and these agents are often used as combination regimens.

In 2013, it was estimated that 95,688 people were living with multiple myeloma (MM) in the United States.1

There is now availability of numerous chemotherapeutic options for MM treatment and these agents are often used as combination regimens.

In 2013, it was estimated that 95,688 people were living with multiple myeloma (MM) in the United States.1

There is now availability of numerous chemotherapeutic options for MM treatment and these agents are often used as combination regimens.

In 2013, it was estimated that 95,688 people were living with multiple myeloma (MM) in the United States.1

There is now availability of numerous chemotherapeutic options for MM treatment and these agents are often used as combination regimens.

In 2013, it was estimated that 95,688 people were living with multiple myeloma (MM) in the United States.1

There is now availability of numerous chemotherapeutic options for MM treatment and these agents are often used as combination regimens.

In 2013, it was estimated that 95,688 people were living with multiple myeloma (MM) in the United States.1

There is now availability of numerous chemotherapeutic options for MM treatment and these agents are often used as combination regimens.

In 2013, it was estimated that 95,688 people were living with multiple myeloma (MM) in the United States.1

There is now availability of numerous chemotherapeutic options for MM treatment and these agents are often used as combination regimens.

In 2013, it was estimated that 95,688 people were living with multiple myeloma (MM) in the United States.1

There is now availability of numerous chemotherapeutic options for MM treatment and these agents are often used as combination regimens.

In 2013, it was estimated that 95,688 people were living with multiple myeloma (MM) in the United States.1

There is now availability of numerous chemotherapeutic options for MM treatment and these agents are often used as combination regimens.

In 2013, it was estimated that 95,688 people were living with multiple myeloma (MM) in the United States.1

There is now availability of numerous chemotherapeutic options for MM treatment and these agents are often used as combination regimens.

In 2013, it was estimated that 95,688 people were living with multiple myeloma (MM) in the United States.1

There is now availability of numerous chemotherapeutic options for MM treatment and these agents are often used as combination regimens.

In 2013, it was estimated that 95,688 people were living with multiple myeloma (MM) in the United States.1

There is now availability of numerous chemotherapeutic options for MM treatment and these agents are often used as combination regimens.

In 2013, it was estimated that 95,688 people were living with multiple myeloma (MM) in the United States.1

There is now availability of numerous chemotherapeutic options for MM treatment and these agents are often used as combination regimens.

In 2013, it was estimated that 95,688 people were living with multiple myeloma (MM) in the United States.1

There is now availability of numerous chemotherapeutic options for MM treatment and these agents are often used as combination regimens.

In 2013, it was estimated that 95,688 people were living with multiple myeloma (MM) in the United States.1

There is now availability of numerous chemotherapeutic options for MM treatment and these agents are often used as combination regimens.

In 2013, it was estimated that 95,688 people were living with multiple myeloma (MM) in the United States.1

There is now availability of numerous chemotherapeutic options for MM treatment and these agents are often used as combination regimens.

In 2013, it was estimated that 95,688 people were living with multiple myeloma (MM) in the United States.1

There is now availability of numerous chemotherapeutic options for MM treatment and these agents are often used as combination regimens.

In 2013, it was estimated that 95,688 people were living with multiple myeloma (MM) in the United States.1

There is now availability of numerous chemotherapeutic options for MM treatment and these agents are often used as combination regimens.